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The destabilizing p53 cancer mutation Y220C cre-
ates an extended crevice on the surface of the
protein that can be targeted by small-molecule stabi-
lizers. Here, we identify different classes of small
molecules that bind to this crevice and determine
their binding modes by X-ray crystallography. These
structures reveal two major conformational states of
the pocket and a cryptic, transiently open hydropho-
bic subpocket that is modulated by Cys220. In one
instance, specifically targeting this transient protein
state by a pyrrole moiety resulted in a 40-fold in-
crease in binding affinity. Molecular dynamics simu-
lations showed that both open and closed states of
this subsite were populated at comparable fre-
quencies along the trajectories. Our data extend
the framework for the design of high-affinity Y220C
mutant binders for use in personalized anticancer
therapy and, more generally, highlight the impor-
tance of implementing protein dynamics and hydra-
tion patterns in the drug-discovery process.
INTRODUCTION
The rational design of potent, pharmacologically active chemical
probes to target disease-related proteins is aided by a detailed
understanding of the target protein structure, its conformational
flexibility, availablemolecular interactions, andsolvation patterns
(Bissantz et al., 2010; Teague, 2003). Proteinmolecular dynamics
(MD) simulations may help to identify induced-fit mechanisms of
ligand binding, modulate potential interaction networks, and
reveal surface properties not observed in the available crystal
structures. For several pharmaceutically relevant targets, MD
simulations suggest the presence of cryptic, only transiently
open binding pockets or subpockets (Bernini et al., 2014; Kokh
et al., 2013; Wassman et al., 2013). Using a single static crystal
structure of a ligand-free protein for rational drug design may
miss intrinsic flexibility of binding sites. Insights into the structural
plasticity of a binding pocket can, however, be obtained from an
ensemble of different crystal structures, for example by2246 Structure 23, 2246–2255, December 1, 2015 ª2015 The Authorcomparing the structure of the target protein in different crystal
forms or different molecules within an asymmetric unit, or by
analyzing binding-pocket variations in structures with different li-
gands. The latter approach has recently led to the identification of
transient conformational states of the N-terminal domain of the
MDM2 protein that can be exploited for the design of inhibitors
of the p53-MDM2 interaction (Bista et al., 2013).
The tumor-suppressor protein p53 is a prime target for thera-
peutic intervention in cancer. It is inactivated in virtually every tu-
mor either through missense mutation in the p53 gene or as a
result of perturbations in its regulatory pathways, for example
by overexpression of its negative regulators MDM2 and MDMX
(Joerger and Fersht, 2010; Khoo et al., 2014; Uversky et al.,
2014; Wade et al., 2013). Most oncogenic p53 mutations are
located in the DNA binding domain (DBD) and either cause
loss of essential contacts with DNA (contact mutants) or perturb
the structure of this domain (structural mutants) (Joerger and
Fersht, 2007). Because of its low intrinsic stability, the DBD is
very susceptible to inactivation by destabilizing mutations,
causing the protein to rapidly unfold, aggregate, and lose its
transcriptional activity (Bullock et al., 2000; Wilcken et al.,
2012b). In principle, it should be possible to rescue the tumor-
suppressor function of these structural mutants with small mol-
ecules that selectively bind to the folded but not the denatured
state of the mutant protein, thereby shifting its conformational
equilibrium and stabilizing an active, wild-type-like conforma-
tion. The cancer mutation Y220C, which accounts for an esti-
mated 100,000 new cancer cases per year worldwide (Joerger
and Fersht, 2007), is an ideal test case for this rescue strategy
withmolecular chaperones. Mutation of a tyrosine on the surface
of the protein to a smaller cysteine residue opens up an extended
but narrow crevice that can be targeted by small molecules
(Joerger et al., 2006). By using virtual screening, we discovered
a carbazole derivative, PhiKan083 (1), which binds to the Y220C
pocket, raises the melting temperature of the protein, and slows
down its rate of aggregation (Boeckler et al., 2008). We subse-
quently identified additional, chemically diverse molecules that
bind to the mutation-induced surface crevice in the Y220C
mutant (Basse et al., 2010; Wilcken et al., 2012a) and synthe-
sized a molecule that is biologically active in cancer cell lines
with homozygous Y220C mutation (Liu et al., 2013), establishing
the proof of concept that functional restoration of mutant p53 by
small molecules is a viable strategy.s
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Figure 1. Mutation-Induced Surface Crevice in the p53 Cancer
Mutant Y220C
Molecular surface representation of the binding pocket in complex with the
carbazole derivative PhiKan083 (1) (PDB: 2VUK). The binding pocket can be
formally subdivided into a central cavity (blue) and subsites I (red), II (green),
and III (magenta). In the ligand-free structure and the complex with PhiKan083,
subsite III is blocked by the Cys220 side chain.Here, we report high-resolution crystal structures of the Y220C
mutant bound to a series of structurally diverse small-molecule
compounds that were identified through screening of fragment
libraries or developed through structure-based design strate-
gies. CombinedwithMD simulations, these data provide insights
into the structural plasticity of the mutation-induced surface
crevice, revealing a transiently open hydrophobic subpocket,
and pinpoint key interactions for the design of binders with
increased potency.RESULTS AND DISCUSSION
Overall Architecture of the Y220C Binding Pocket
The Y220C mutation creates an extended but narrow crevice on
the surface of the p53 protein (Joerger et al., 2006). This crevice
is flanked by two proline-rich loops, S3/S4 and S7/S8, and has
its greatest depth at the mutation site. The binding site can
formally be subdivided into a central cavity and three subsites,
I, II, and III (Figure 1). PhiKan083 (1), the first structurally charac-
terized Y220C binder, is sandwiched between several prolines
(Pro151, Pro222, and Pro223) and Val147 in the central cavity,
with the ethyl group serving as a hydrophobic anchor. It extends
into subsite I via its methylamine linker, where it forms a
hydrogen bond with the backbone oxygen of Asp228. This
shallow, solvent-exposed subsite is largely polar, making its tar-
geting by small molecules difficult. A narrow channel on the
opposite end of the central cavity leads into subsite II, where
several prolines, including Pro153, provide a hydrophobic inter-
action surface, with several backbone oxygens lining this hydro-
phobic patch (Cys220, Pro151, and Pro152). As we outline inStrudetail in the following, there is an additional, transiently open
subsite III at the bottom of the central cavity, which is essentially
modulated by the conformational state of Cys220.
Crystal Structures of Y220C-Ligand Complexes
From screening of fragment libraries combined with structure-
based design, we have identified a series of chemically diverse
compounds that bind to the Y220C mutant with varying affinities
and have determined their binding mode by X-ray crystallog-
raphy (Figure 2; Tables 1 and 2). Together with our previously
published Y220C-ligand structures, they provide snapshots of
the dynamic nature of the binding site and highlight key interac-
tions for the design of potent binders. The first striking aspect
upon analysis of these structures is that the various small mole-
cules sample two different conformational states of the binding
pocket that are essentially modulated by Cys220 (Figure 2). Ro-
tamer switch of the side chain of Cys220 from trans to gauche()
conformation opens up a small hydrophobic pocket at the bot-
tom of the binding site (subsite III). In the ‘‘closed’’ state with
trans conformation of the Cys220 side chain, which is observed
in the ligand-free structure, the sulfur is solvent exposed,
whereas it contacts several hydrophobic residues in the
‘‘open’’ state of the pocket with gauche() conformation of
Cys220. Rotation of the cysteine side chain is generally also
accompanied by small changes in the backbone conformation.
Conformational flexibility in the subsite III region is not restricted
to Cys220 but also extends further into the hydrophobic core of
the b-sandwich region. Both Val157 and Ile232 adopt alternative
side-chain conformations, depending on the bound ligand,
which is indicative of the dynamic nature of this region of the
binding pocket. Alternative conformations are also observed
for the side chain of Thr230.
Ligand Binding Modes and Conformational Selection
The structures of Y220C with different indole-based fragments
provided insights into the structural plasticity of the binding
site. The binding mode of fragment 2 mimics that of the carba-
zole-based PhiKan083 (1, Figure 3A). The indole ring binds to
the center of the binding pocket and is sandwiched between
Pro223 on one side and Val147/Pro151 on the other side. The
indole nitrogen forms a hydrogen bond with the backbone
carbonyl of Leu145, thereby displacing a structural water mole-
cule. The ethyl group serves as a hydrophobic anchor at the bot-
tom of the binding pocket. The piperidinemoiety reaches into the
solvent and contributes little to the overall binding. Interestingly,
additional methyl/bromo substituents on the indole scaffold and
a shorter,more flexible linker to the protonated amine in fragment
6 completely alter the binding mode of the fragment within the
Y220C pocket (Figure 3A). It binds to the ‘‘open’’ state of subsite
III. The central indole moiety sits upright within the pocket, occu-
pying different parts of the central cavity than fragment 2, and the
bromo moiety points into subsite III where it forms hydrophobic
interactions. This example illustrates both the conformational
plasticity of the binding pocket and the fact that the same scaf-
fold, depending on its substitution pattern, can select different
conformational states and target different subsites of the pocket.
The 2,4,5-substituted oxazole 10 and the 1,3,4-substituted
pyrazole 7 (PhiKan7242) represent another interesting com-
pound pair with regard to their conformational selection. In thiscture 23, 2246–2255, December 1, 2015 ª2015 The Authors 2247
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Figure 2. Small-Molecule Stabilizers of the p53 Cancer Mutant Y220C
(A) Chemical structures of compounds binding to the mutation-induced surface crevice in p53-Y220C. Compounds are grouped according to the conformational
state of the Y220C pocket (closed or open subsite III) in the structure of the complex.
(B) Molecular surfaceof theY220Cpocket (cross section) in complexwith5. TheCys220sulfur atomfaces thesolvent andblocks subsite III. Thebromineatom forms
a halogen bond (broken magenta line) with the backbone oxygen of Leu145 with near ideal bond geometry (distance = 3.0 A˚, s-hole angle [Car-Br$$$O] = 174
).
(C) Molecular surface of the Y220C pocket (cross section) in complex with 10. In this case, Cys220 adopts an alternative conformation with the sulfur pointing
toward the interior of the protein, thereby opening up a hydrophobic subpocket (subsite III), which is occupied by the pyrrole moiety of the ligand.
Yellow broken lines in (B) and (C) indicate water-mediated hydrogen bonds. Water molecules are shown as small red spheres.case, both molecules bind to the ‘‘open’’ conformation of the
binding pocket and target subsite III via a pyrrole moiety (Fig-
ure 3B). Despite the different position of the central ring system
in the binding pocket, the pyrrole moieties occupy essentially the
same position and engage in extensive hydrophobic interactions
within the transiently open subsite III (e.g., with Leu145, Val147,
Cys220, and Leu257). In both cases, the second hydrophobic
substituent (4-fluorophenyl/cyclopropyl) points toward subsite
II. The tetrazole in 10 is solvent exposed and interacts with two
conserved structural water molecules. We have recently shown2248 Structure 23, 2246–2255, December 1, 2015 ª2015 The Authorthat PhiKan7088, an analog of 7, is biologically active in cancer
cell lines expressing the Y220C mutant (Liu et al., 2013), which
highlights the potential of ligands that effectively target subsite
III for future cancer therapy.
Exploiting the Transiently Open Subsite III for Ligand
Design
Analysis of the binding modes of the iodophenol series (e.g., 3)
and molecule 7 suggested merging of these compound series.
We therefore designed hybrid compounds to evaluate thes
Table 1. X-Ray Data Collection and Refinement Statistics of p53-Y220C Ligand Structures
Compound 2 5 6 9 10 11 12
Data Collection
Space group P212121 P212121 P212121 P212121 P212121 P212121 P212121
a (A˚) 64.99 64.89 64.82 65.22 65.01 64.91 65.16
b (A˚) 71.06 71.11 71.18 71.11 70.99 71.24 71.27
c (A˚) 105.03 104.94 104.81 105.35 105.18 105.02 105.11
Molecules/AU 2 2 2 2 2 2 2
Resolution (A˚)a 29.6–1.36
(1.43–1.36)
29.5–1.62
(1.71–1.62)
29.5–1.78
(1.88–1.78)
29.5–1.47
(1.55–1.47)
29.5–1.35
(1.42–1.35)
35.4–1.50
(1.58–1.50)
43.7–1.74
(1.83–1.74)
Unique reflections 103,976 61,994 46,975 83,461 103,354 78,962 49,879
Completeness (%)a 99.2 (98.6) 99.4 (98.8) 99.6 (99.4) 99.4 (99.4) 96.5 (94.2) 99.8 (99.6) 98.2 (96.7)
Multiplicitya 5.4 (5.4) 6.0 (5.9) 4.9 (4.9) 5.4 (5.4) 6.1 (5.9) 5.6 (5.3) 5.6 (5.4)
Rmerge (%)
a 5.4 (59.5) 8.6 (54.3) 5.1 (63.0) 6.0 (55.7) 6.3 (46.3) 7.3 (33.5) 7.0 (34.9)
Mean I/sIa 15.2 (3.7) 14.5 (3.3) 16,9 (3.2) 13.4 (3.1) 15.5 (3.7) 14.0 (4.1) 14.9 (4.7)
Wilson B value (A˚2) 13.0 14.3 22.8 14.0 11.2 12.7 16.3
Refinement
Rwork (%)
b 14.3 17.8 17.8 14.9 14.5 13.9 16.9
Rfree (%)
b 16.6 20.3 20.6 17.8 16.9 16.9 19.1
No. of atoms
Proteinc 3187 3129 3113 3135 3180 3217 3104
Zinc 2 2 2 2 2 2 2
Water 425 480 334 406 566 554 440
Ligands 70 46 23 41 49 13 64
RMSD bonds (A˚) 0.006 0.006 0.007 0.006 0.006 0.006 0.007
RMSD angles () 1.0 1.0 1.0 1.0 1.1 1.0 1.0
Mean B (A˚2) 21.0 17.8 31.4 21.0 16.5 18.0 21.2
PDB entry 5AB9 5ABA 5AOI 5AOJ 5AOK 5AOL 5AOM
RMSD, root-mean-square deviation.
aValues in parentheses are for the highest-resolution shell.
bRwork and Rfree =
PjjFobsj  jFcalcjj/
PjFobsj, where Rfree was calculated with 5% of the reflections chosen at random and not used in the refinement.
cNumber includes alternative conformations.potential gain in affinity by introducing a pyrrole moiety that tar-
gets the open state of subsite III. Based on this rational design
strategy, we synthetically introduced a pyrrole in position 4 of
the 3,5-diiodo-salicylic acid scaffold 4 (KD = 820 mM; ligand
efficiency [LE] = 0.35 kcal/mol per non-hydrogen atom). The re-
sulting compound 9 (KD = 21 mM; LE = 0.38) displayed a 40-fold
increase in affinity and maintained high LE, thus highlighting an
important design criterion based on subsite III exploration to
develop potent ligands (Table 2). Determination of the crystal
structure of 9 in complex with Y220C confirmed that the pyrrole
moiety binds to the open state of subsite III as anticipated. Inter-
estingly, the presence of the pyrrole did not significantly affect
the binding mode of the central scaffold, which retained its inter-
action network, including the halogen bond to the carbonyl oxy-
gen of Leu145 (Figure 4A).
Intriguingly, the crystal structure of the Y220C-10 complex re-
vealed a bound glycerol molecule close to the pyrrole moiety in
subsite III. This glycerol, which was trapped from the soaking
buffer, forms hydrogen bonds with the main-chain oxygen of
Pro219, the main-chain nitrogen of Glu221, the side chain of
Thr230, and the main-chain oxygen of Thr231, as well as a num-
ber of structural water molecules (Figure 4B). The closest dis-Strutance between the glycerol and the pyrrole moiety of 10 is
3.3 A˚, but there is no channel connecting both binding sites. In
this context, the binding mode of the small fragment 11 is of
particular interest (Figure 4D). It is buried deeply within subsite
III and forms hydrophobic interactions with Leu145, Val157,
Leu257, Phe109, and a hydrogen bond with the main-chain ox-
ygen of Pro222. The protein backbone around Pro222 is signifi-
cantly displaced upon ligand binding (up to 3.5 A˚), which further
increases the depth and width of subsite III. This movement con-
nects subsite III with the glycerol binding site, indicating that the
Y220C mutant protein may sample a conformation with a tran-
siently open channel in solution (Figures 4C and 4D). Future
design strategies may therefore exploit the structural plasticity
of the binding pocket, and introduce subsite III moieties that
probe the conformational ensemble of this region and potentially
extend into the glycerol binding site.
The Role of Structural Water Networks within the
Binding Pocket
Determining the hydration pattern of protein binding sites aids
the understanding of ligand binding and improving ligand affinity
(Bissantz et al., 2010). There is a network in the ligand-freecture 23, 2246–2255, December 1, 2015 ª2015 The Authors 2249
Table 2. Dissociation Constants of p53-Y220C Ligand
Complexes
Compound KD (mM)
a
1 125 ± 10 (ITC)b
2 470 ± 90 (NMR)
3 9.7 (ITC)c
4 820 ± 70 (NMR)c
5 1,040 ± 110 (NMR)c
6 940 ± 110 (NMR)
7 2,400 ± 300 (NMR)
8 >10,000 (NMR)
9 21 (ITC)
10 >2,000 (NMR)
11 4,800 ± 900 (NMR)
12 1,270 ± 570 (NMR)
13 ND
aThe method used for determination of the dissociation constant is given
in parentheses: nuclear magnetic resonance spectroscopy (NMR) or
isothermal calorimetry (ITC). ND, not determined.
bData taken from Boeckler et al. (2008).
cData taken from Wilcken et al. (2012a).
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Figure 3. Differential Conformational Selection of p53-Y220C
Ligands
(A) Superposition of the structures of two indole derivatives, 2 (green ligand,
salmon protein chain) and 6 (yellow ligand, gray protein chain), in complex with
p53-Y220C. Despite sharing a common scaffold, the two compounds adopt
different binding modes and target a different conformational state of the
Y220C pocket. The hydrogen bond between 2 and the backbone oxygen of
Leu145 is highlighted with a dashed magenta line.
(B) Superposition of the structures of 7 (yellow ligand, gray protein chain; PDB:
3ZME) and 10 (green ligand, salmon protein chain) in complex with p53-
Y220C. Both compounds target the same conformational state of the Y220C
pocket and bind to the open state of subsite III via a pyrrole moiety. In-
teractions with selected structural water molecules are highlighted with
dashed lines.crystal structure of the Y220Cmutant of several water molecules
in the mutation-induced cavity (Figure 5). Two adjacent water
molecules, which are also present in the wild-type structure,
exhibit on average lower B factors than the remaining waters in
the cavity and form a well-defined hydrogen-bond network (wa-
ter molecules W1 and W2 in Figure 5). One of these waters (W1)
sits at the entrance toward subsite I and connects two carbonyl
oxygens from different loops of the binding pocket (Val147 and
Asp228). The second water (W2) lies more centrally within the
pocket, where it forms a hydrogen bond with the Leu145 back-
bone oxygen and Thr230. Depending on the chain in the crystal
structure, the hydrogen bond is formedwith either the side-chain
hydroxyl or the main-chain nitrogen. In the wild-type structure,
structural water W2 is further stabilized via a hydrogen bond
with the hydroxyl group of Tyr220. It is displaced in most ligand
complexes, except for 10 and 7, where the small molecules form
a hydrogen bond with the structural water (Figure 3B). Upon wa-
ter displacement, most ligands made polar interactions with the
Leu145 backbone, through either a hydrogen or halogen bond
(see Figures 2A and 3A), mimicking the water-mediated interac-
tion and compensating for the enthalpic cost of water displace-
ment. W1 was retained in many ligand structures and often
formed part of the polar ligand interaction network. Although
there are several accessible backbone carbonyl oxygens within
subsite II that can act as hydrogen-bond acceptors (e.g., back-
bone of Pro152, Pro153, and Cys220), the solvent structure in
this region was generally less well defined in the available crystal
structures.Targeting Subsite II
For several aromatic fragments we detected two ligand mole-
cules bound in close proximity within the Y220C binding
pocket: one at the center of the binding site and another in
subsite II. The electron density for the second molecule was2250 Structure 23, 2246–2255, December 1, 2015 ª2015 The Authorgenerally much weaker, indicating partial occupancy because
of lower affinity for this secondary binding site. An example
is compound 12. Binding of 12 induced a rotamer switch of
Cys220 (Figure 6A). In the primary binding mode, the chloro-
phenol moiety sits deep inside the central cavity, with its
hydroxyl group forming hydrogen bonds with the main-chain
oxygen of Leu145 and the conserved structural water molecule
W1 between the backbone carbonyl of Asp228 and Val147.
The chlorine faces the narrow hydrophobic channel toward
subsite II. The amide group accepts a hydrogen bond froms
AP153
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Figure 4. Targeting the Transiently Open
Subsite III
(A) Superposition of the bindingmodes of 9 (green)
and its precursor chemotype without pyrrole
moiety (yellow ligand, gray protein chain; PDB:
4AGL) shows that the pyrrole moiety binds to the
open state of subsite III, without significant effect
on the overall bindingmode of the central scaffold.
The protein chains are shown as Ca traces, and
the small molecules and selected protein residues
as stick models. The broken magenta line in-
dicates the halogen bond formed by one of the
iodine substituents with the backbone oxygen of
Leu145. Hydrogen bonds of 9 with Thr150 and a
structural water molecule are highlighted with
green broken lines.
(B) Structure of the Y220C-10 complex with bound
glycerol. As in (A), the protein is shown as a Ca
trace with selected residues highlighted as stick
models. 10 is shown in pink. A glycerol molecule
trapped from the soaking buffer, shown as a green
stickmodel, binds close to the pyrrolemoiety of 10
but outside the Y220C pocket. Hydrogen bonds
between protein and glycerol are highlighted with
orange broken lines.
(C) Molecular surface representation of the glyc-
erol binding site in the Y220C-10 complex.
(D) Molecular surface representation of the Y220C
mutant in complex with 11. Fragment 11 (yellow
stickmodel) has a unique bindingmode, and binds
between the binding sites of the pyrrole moiety of
10 and the glycerolmolecule (both shown as green
stick models). As a result, binding of 11 opens up
and stabilizes a small channel that links subsite III
and the glycerol binding site.Thr150 with its carbonyl oxygen and donates a hydrogen bond
to the structural water W1 via its amide NH. The piperidine
moiety protrudes into the solvent, similarly to its position in
the Y220C-2 complex. A second molecule of 12 binds to sub-
site II where the aromatic ring packs against Pro153 and
Pro222, and the chlorine substituent faces the hydrophobic
channel connecting subsites II and III. This binding mode is
reminiscent of that observed for the previously published diani-
line 8 (Basse et al., 2010). Interestingly, a second molecule
binding to subsite II was also observed for indole 2 (Figure 6B).
Here, the indole ring is also engaged in hydrophobic interac-
tions with Pro153/Pro222 and, additionally, forms a hydrogen
bond with the backbone carbonyl of Pro151. A common
feature of these substituted ring systems is that they are
electron rich, combining the appropriate shape complemen-
tarity, hydrophobic interactions, and CH-p interactions with
Pro153/Pro222. Introducing a benzene moiety in subsite II
via an acetylene linker was also crucial for improving the affin-
ity of the iodophenol series, e.g., in compound 3 (Figure 6C)
(Wilcken et al., 2012a). In addition, Cys220 and Pro151 provide
hydrogen-bond acceptors in an ideal orientation for hydrogen-
bond formation. Taken together, these data show that subsite
II and the channel leading into it are poised for interaction
with appropriately substituted aromatic ring systems that
combine significant electron density on the ring with a favor-
able hydrogen-bond donor/acceptor pattern (e.g., with
Cys220 and Pro151).StruMolecular Dynamics Simulation of the Y220C Binding
Pocket
We performed MD simulations of the Y220C structure to obtain
further insights into the dynamics of the binding pocket. Simula-
tions were run for a total of 900 ns with three different starting
structures (300 ns each): unbound Y220C (PDB: 2J1X), Y220C-
PhiKan784 complex (PDB: 4AGL; closed subsite III) and
Y220C-7 complex (PDB: 3ZME; open subsite III). The ligands
were removed before the start of the simulations. Structures
along the trajectory were clustered based on the conformation
of the Cys220 region as well as the overall architecture of the
binding pocket. As expected, the pocket exhibited significant
plasticity in these simulations. We observed both open and
closed states of subsite III, independent of the starting structure,
with two major side-chain conformations of Cys220, with c1 an-
gles (N-Ca-Cb-Sg) of about60 for rotamer I (gauche() = ‘‘g’’)
and 180/180 for rotamer II (trans = ‘‘t’’), respectively (Fig-
ure 7C). In addition, there was a third Cys220 rotamer with a c1
angle of about 60 (gauche(+) = ‘‘g+’’), not observed in any crys-
tal structure, which occurred less frequently along the trajectory.
The population of these rotamer clusters over all simulations was
about 38% (rotamer cluster I), 48% (rotamer cluster II), and 14%
(rotamer cluster III). This distribution is close to published gener-
alized rotamer statistics (e.g., DYNAMEOMICS) (Kehl et al.,
2008). The fact that Cys220 conformations corresponding to
both open and closed states of subsite III were populated with
comparable frequency along the trajectory indicates a lowcture 23, 2246–2255, December 1, 2015 ª2015 The Authors 2251
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Figure 6. Targeting Subsite II with Aromatic Systems
Structure of the Y220Cmutant in complex with the chlorophenol 12 (A) and the
indole 2 (B), showing that in both cases two small molecules bind to the Y220C
pocket, one at the center (a) and one in subsite II (b). The binding mode of the
molecules in subsite II is reminiscent of that of the aniline moiety of molecule 3
(C), which also packs against Pro153 (PDB: 4AGQ). Polar interactions
(hydrogen and halogen bonds) between the small molecules and the protein or
conserved structural water molecules are highlighted with green broken lines.
All three structures are shown in approximately the same orientation.
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Figure 5. Hydration Pattern of the Y220C Pocket
Molecular surface representation of a cross section of the mutation-induced
surface crevice in p53-Y220C (PDB: 2J1X, chain A). Structural water mole-
cules inside the pocket are shown as spheres and colored according to their
B factors in a rainbow-colored gradient from blue (B factor = 15 A˚2) to red
(B factor = 50 A˚2). The B factors over all water molecules in chain A of the
structure range from 8 to 53 A˚2. Particularly stable water molecules are labeled
W1 and W2. Orange broken lines indicate hydrogen bonds.energy barrier for the Cys220 side-chain rotation in the binding
pocket, suggesting that it also fluctuates between alternative
conformations in solution.
The width of the binding pocket varies significantly in the
different Y220C crystal structures (Figure 7A). The observed dis-
tance between the Ca atoms of Thr150 and Pro222 at the rim of
the surface crevice, for example, ranges from 7.1 to 8.8 A˚, de-
pending on the ligand bound. In the wild-type structure (PDB:
2XWR; Natan et al., 2011), this distance is 6.7 A˚ in chain A and
6.9 A˚ in chain B. Modulation of this distance in the Y220C-ligand
complexes is largely due to a movement of the S7/S8 loop,
whereas the shorter S3/S4 loop comprising Thr150 is more rigid
and shows only minor shifts upon ligand binding. Both loops are
not directly involved in crystal contacts. In the simulations, how-
ever, there were substantial fluctuations in both loops, with a
general movement of the S3/S4 loop toward the center of the
pocket (Figures 7B and 7D). Pro151, for example, showed a ten-
dency to collapse into the pocket and interacted with Pro223 in
some structures along the trajectory (especially in the first 100-
ns simulation with PDB: 2J1X as a starting structure), which
essentially blocked parts of the central cavity. In the remainder
of the simulations, the pocket remained largely open. Overall,
the simulations highlight the highly dynamic nature of the binding
pocket in the absence of stabilizing ligands and support the
notion that there are transiently open subpockets in solution. In
the wild-type structure, S3/S4 and S7/S8 loop movements are
restricted by the side chain of Tyr220 (Basse et al., 2010).
Conclusions
The crystal structures of the p53 cancer mutant Y220C bound to
stabilizing small molecules provided novel insights into key2252 Structure 23, 2246–2255, December 1, 2015 ª2015 The Authors
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Figure 7. Conformational Flexibility of the Y220C Pocket
(A) Superposition of the binding pocket in different crystal structures, showing shifts in the S7/S8 loop upon ligand binding that modulate the width of the binding
pocket. Ca traces are shown for: ligand-free Y220Cmutant (PDB: 2J1X) chains A (blue) and B (yellow), Y220C-12 complex chain B (magenta), Y220C-10 complex
chain B (green), Y220C-7 complex chain B (cyan), and Y220C-1 complex chain B (gray; PDB: 2VUK). Boundmolecule 12 is shown as a stick model. The distance
between the Ca atoms of Thr150 and Pro222 in the Y220C-12 complex is highlighted with a magenta broken line.
(B) Superposition of representative structures from major clusters along the MD trajectory onto chains A (blue) and B (yellow) of the ligand-free crystal structure.
The gray and magenta Ca traces are representative structures of the two largest clusters with an open pocket, comprising more than half of all structures along
the trajectory. The green structure represents an ensemble of structures with a partial hydrophobic collapse of the pocket via interactions between Pro151 and
Pro223. The close distance between the Cd atoms of Pro151 and Pro223 in this structure is highlighted with a green broken line. The view is the same as in (A).
(C) Side-chain conformations of Cys220 (c1 angle) along the MD trajectories. The conformation fluctuates between different rotamers corresponding to an open
and close state of subsite III. Broken lines indicate starting points of different MD simulations, and those in red a new starting structure.
(D) Distance between the Ca atoms of Thr150 and Pro222 (top), and between the Cd atoms of Pro151 and Pro223 (bottom) as a function of time over all sim-
ulations. The solid magenta lines indicate the largest and smallest distances observed in the various Y220C crystal structures. Starting and end points of the
various simulations are the same as in (C).protein-ligand interactions, hydration patterns, and conforma-
tional states of the binding pocket. Importantly, we have identi-
fied a transiently open subpocket (subsite III), which is blocked
by the Cys220 side chain in the crystal structure of the ligand-
freemutant. Targeting this hydrophobic site with a pyrrolemoiety
resulted in substantial gains in affinity. The structural data and
associated structure-activity relationships provide the blueprint
for the design of high-affinity binders, for example by merging
existing core scaffolds, or modifications thereof, with optimized
subsite II and subsite III moieties. Such high-affinity ligands mayStruact as potent anticancer agents and provide valuable chemical
probes for studying p53 function in living cells.
More generally, our data highlight the usefulness of crystallo-
graphic validation of ligand binding modes early in the drug-dis-
coveryprocess.Screeningof fragment libraries is perfectly suited
formapping theconformational ensembleof abinding site and for
identifying cryptic subpockets, as shown here for the p53 Y220C
mutant. Such a strategy allows targeting of transient protein
states and increases the chancesof finding ligandswith newche-
motypes and physicochemical properties that would not havecture 23, 2246–2255, December 1, 2015 ª2015 The Authors 2253
been discovered with docking or rational drug discovery based
solely on a single crystal structure of the apo protein.
EXPERIMENTAL PROCEDURES
Chemical Compounds
Compounds 2 and 12 were bought from Enamine, compound 5 from
Chembridge (custom-made synthesis contract), compound 6 from Vitas-M
Laboratory, and compound 11 from Sigma-Aldrich. Synthesis of compounds
9 and 10 will be described elsewhere.
Binding Assays
Dissociation constants for the binding of ligands to the p53 Y220C mutant
were determined by either nuclear magnetic resonance spectroscopy or
isothermal calorimetry as described by Wilcken et al. (2012a).
Structure Determination of Y220C-Ligand Complexes
Crystals of p53C-Y220Cwere grown at 18Cusing the sitting-drop vapor diffu-
sion technique as described by Joerger et al. (2006). Crystals were soaked for
3–6 hr in a 30–40 mM solution of compound in cryo buffer (19% polyethylene
glycol 4000, 20%glycerol, 10mMsodium phosphate [pH 7.2], 100mMHEPES
[pH 7.2], and 150 mM NaCl). In case of poor ligand solubility, saturated solu-
tions were used for soaking. X-Ray data were collected at 100 K at the beam-
lines I02, I03, and I04 of the Diamond Light Source (Oxford, UK). Datasets were
indexed using either MOSFLM (Battye et al., 2011) or XDS (Kabsch, 2010), and
scaled using the program SCALA (Evans, 2006) within the CCP4 software suite
(Winn et al., 2011). The structures of the Y220C-ligand complexes were then
solved using difference Fourier methods (rigid body refinement using PDB:
2J1X as a starting model), and refined using iterative cycles of manual model
building in Coot (Emsley et al., 2010) and refinement with PHENIX (Adams
et al., 2010). In the complex with compound 6, the small molecule could
only be modeled for one of the two chains in the asymmetric unit (chain B).
Compound 11 was observed only in chain A and refined with partial occu-
pancy. In this case, loop residues 219–224 in chain A were refined in two alter-
native conformations corresponding to the bound and unbound states. In the
structure with 9, there was significant negative difference density at the center
of the iodine atom that is not involved in halogen bonding and significant
positive difference density extending from the iodine into subsite 2, suggesting
radiation damage and breakage of the C-I bond during data collection. X-Ray
data collection and refinement statistics are given in Table 1. Structural figures
were prepared using PyMOL (www.pymol.org).
Molecular Dynamics Simulations
MD calculations were performed with the AMBER 12 suite of programs using
three different starting structures of the Y220Cmutant (PDB: 2J1X, 3ZME, and
4AGL). Protein parameters were taken from parm12SB, a modified version of
the Cornell force field (Cornell et al., 1995; Hornak et al., 2006), and zinc param-
eters were taken from Bradbrook et al. (1998). Long-range electrostatic inter-
actions were computed using the particle mesh Ewald method (Darden et al.,
1993), and covalent bonds to hydrogen atomswere constrained by the SHAKE
algorithm (Ryckaert et al., 1977). The time step was set to 2 fs with a non-
bonded cutoff of 9 A˚. Structural waters and ligands were removed before
the start of the simulations, and the protein was placed in a truncated octahe-
dral TIP4Pew water box with periodic boundary conditions (Horn et al., 2004).
The box boundaries were at least 12 A˚ away from protein atoms. Chlorine ions
were added to maintain electroneutrality of the system. The system was then
equilibratedwith 1,000 steps of minimization, followed by heating to 300 K dur-
ing 10 ps of canonical ensemble (NVT) MD and by finally relaxing the pressure
to 1 bar during 5 ns of isothermal-isobaric ensemble (NPT) MD to ensure cor-
rect water distribution close to the protein surface and at the box boundaries.
Harmonic restraints with force constants of 5 kcal mol1 A˚2 were applied to all
protein atoms. These restraints were then gradually reduced to zero during
500 ps of NVT MD, followed by 10 ns of equilibration. A production run of
100 ns followed. The same procedure was repeated four times for each
starting structure with different starting velocities to improve sampling. Only
50-ns-long production runs were performed for these repeat runs. In total,
900 ns (300 ns for each starting structure) were analyzed.2254 Structure 23, 2246–2255, December 1, 2015 ª2015 The AuthorACCESSION NUMBERS
The atomic coordinates of the p53 Y220Cmutant crystal structures have been
deposited in the PDB, www.pdb.org (PDB: 5AB9, 5ABA, 5AOI, 5AOJ, 5AOK,
5AOL, and 5AOM).
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